Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Mivacurium Chloride is a short-acting, non-depolarizing neuromuscular blocking agent widely utilized in clinical anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgical procedures. Chemically classified as a benzylisoquinolinium derivative, its molecular formula is C34H58Cl2N2O6, and it carries the CAS Registry Number 79012-57-6. This compound acts by competitively inhibiting acetylcholine at the nicotinic receptors located on the motor endplate of skeletal muscles, thereby preventing nerve impulse transmission and inducing temporary paralysis without affecting consciousness or pain perception.
A distinguishing feature of Mivacurium Chloride is its rapid onset and short duration of action, typically lasting between 12 to 18 minutes following an intravenous dose. This pharmacokinetic profile makes it particularly advantageous for short-duration surgeries or situations requiring frequent re-intubation, such as bronchoscopy or ophthalmic procedures. Unlike some other neuromuscular blockers that rely heavily on hepatic metabolism, Mivacurium is primarily hydrolyzed in the plasma by pseudocholinesterase (butyrylcholinesterase). Consequently, patients with genetic deficiencies in this enzyme may experience prolonged paralysis, necessitating careful preoperative screening or monitoring.
The drug is supplied as a sterile, clear, colorless solution, often stabilized with sodium metabisulfite to prevent oxidation. Its clinical utility extends to various surgical specialties, including otolaryngology, general surgery, and orthopedics, where quick recovery of muscle function is critical for immediate post-operative assessment. While generally safe, potential adverse effects include histamine release, which can lead to transient hypotension, flushing, or tachycardia, particularly when administered rapidly or in high doses. Despite the availability of newer agents like rocuronium or cisatracurium, Mivacurium remains a valuable tool in specific anesthetic protocols due to its favorable metabolic pathway and predictable recovery time, provided patient-specific enzymatic activity is considered.